62.78
+1.09(+1.77%)
Currency In USD
Address
6340 Sequence Drive
San Diego, CA 92121
United States of America
Phone
858 200 0200
Website
Sector
Healthcare
Industry
Medical - Devices
Employees
10200
First IPO Date
April 14, 2005
| Name | Title | Pay | Year Born |
| Mr. Jacob Steven Leach | Interim Chief Executive Officer, President & Chief Operating Officer | 693,108 | 1978 |
| Mr. Kevin Ronald Sayer | Executive Chairman & Chief Executive Officer (Leave of Absence) | 1.29M | 1958 |
| Mr. Girish Naganathan | Executive Vice President & Chief Technology Officer | 423,920 | 1978 |
| Ms. Sadie M. Stern | Executive Vice President & Chief Human Resources Officer | 550,829 | 1975 |
| Mr. Michael Jon Brown | Executive Vice President & Chief Legal Officer | 607,236 | 1970 |
| Mr. Jereme M. Sylvain CPA | Executive Vice President, Chief Financial Officer & Chief Accounting Officer | 621,949 | 1980 |
| Mr. Donald M. Abbey | Executive Vice President of Global Business Services, IT, Quality & Regulatory Affairs | 766,800 | 1967 |
| Mr. Sean Christensen | Vice President of Finance and Investor Relations | 0 | N/A |
| Mr. Jon Coleman | Executive Vice President & Chief Commercial Officer | 0 | 1964 |
| Mr. Matthew Dolan | Executive Vice President of Strategy & Corporate Development | 0 | 1981 |
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system. The company's products candidature comprises Dexcom G7, a next generation G7 CGM system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
